Proton pump inhibitor co-therapy in patients receiving non-vitamin K antagonist oral anticoagulants: current evidence, gastrointestinal bleeding prevention, and clinical considerations - Report - MDSpire
Advertisement
Proton pump inhibitor co-therapy in patients receiving non-vitamin K antagonist oral anticoagulants: current evidence, gastrointestinal bleeding prevention, and clinical considerations
Co-administration of Proton Pump Inhibitors with Non-Vitamin K Antagonist Oral Anticoagulants
Overview
Revise to include that most evidence is observational and may have confounding factors.
Background
As the use of NOACs for stroke prevention in atrial fibrillation increases, gastrointestinal bleeding, especially UGIB, has become a significant concern. The potential for PPIs to mitigate these risks is critical, given that major gastrointestinal bleeding can lead to interruptions in anticoagulation therapy, increasing thromboembolic risks. Understanding the implications of PPI co-therapy is essential for optimizing patient outcomes in anticoagulated populations.
Data Highlights
Study
Findings
Korean Nationwide Cohort
PPI co-therapy associated with reduced UGIB hospitalization (HR 0.825) and transfusion-requiring UGIB (HR 0.798).
Meta-analysis
Lower odds of total and major GIB with PPI use (OR ∼0.67–0.68).
Key Findings
PPI co-therapy is linked to reduced UGIB hospitalization in NOAC-treated patients.
Observational studies indicate lower rates of severe bleeding events with PPI use.
Higher bleeding risks are associated with specific NOAC agents, particularly rivaroxaban.
Patient-level factors such as age and prior peptic ulcer disease increase bleeding risk.
Current guidelines recommend individualized gastroprotection rather than universal PPI use.
Clinical Implications
Highlight the importance of individualized risk assessment and lack of randomized data.
Conclusion
Reiterate the need for randomized trials and address current evidence limitations.
